TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01993589
Drug: comparison of pain relievers
Normalized name: LidoPro Pain Relieving Patch
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01993589
Drug: comparison of pain relievers during curattage
Normalized name: LidoPro Pain Relieving Patch
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02720744
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01619644
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with an oral dosage of 30 mg/kg/jour
Study: NCT01381419
Drug: GSK1144814
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose.
Study: NCT01381419
Drug: GSK1144814
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose which may be split in up to three divided doses given 2 to 3 hours apart.
Study: NCT01011166
Drug: IDX184
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX184 50 mg white opaque capsules taken by mouth from Day 1 to Day 14.
Study: NCT01011166
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo white opaque capsules taken by mouth from Day 1 to Day 14.
Study: NCT01945801
Drug: Lasilactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug (spironolactone 100 mg plus furosemide 20 mg).
Study: NCT01945801
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group will receive cellulose-based placebo pills with identical pills and flasks to active drug.
Study: NCT01381419
Drug: GSK1144814
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose that may be split in up to three divided doses given 2 to 3 hours apart.
Study: NCT00799643
Drug: Salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salsalate 3.5 g/d orally, divided dosing
Study: NCT00799643
Drug: Salsalate Placebo
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02181322
Drug: Meloxicam - low dose
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02181322
Drug: Meloxicam - medium dose
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02181322
Drug: Meloxicam - high dose
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00245297
Drug: Kogenate FS, reconstituted in a suspension of liposomes
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02236806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule daily
Study: NCT01520142
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In both Study Part 1 and Part 2, the participant will receive an oral solution of matching placebo once daily for up to 7 days.
Study: NCT03179293
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be administered manually over the next 3 min prior to the patient leaving the OR
Study: NCT03558490
Drug: Investigator's choice of anti-cancer treatment (except immunotherapy)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All anti-cancer treatments (except immunotherapy) will be left to the free choice of investigators. Participants shall be prescribed by the healthcare team both of the following symptomatic treatments: loperamide or any other anti-diarrheic treatment in case of diarrhea; and a prescription for any medication indicated in case of nausea/vomiting. A written prescription will be made by the investigator at screening for loperamide or any other anti-diarrheic treatment and symptomatic treatment for nausea/vomiting with documented dosage and duration.
Study: NCT00720343
Drug: Choline
Normalized name: Choline
DrugBank: Choline (DB00122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Choline 20 grams before surgery
Study: NCT00720343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin Capsule
Study: NCT01963845
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03229291
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same formulation as topical SM04755 solution, without SM04755 included.
Study: NCT04371445
Drug: Prednisolone Acetate 1% Oph Susp
Normalized name: PREDNISOLONE ACETATE 1% OPH SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone acetate 1% eye drops are used 2-4 times daily for 30 days as the current standard of care for treating inflammation and eye pain after cataract surgery. Prednisolone, like dexamethasone, is a steroid. This arm will also receive the standard of care including topical antibiotics.
Study: NCT03823703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT00162006
Drug: Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01970878
Drug: GP MDI (PT001)
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP MDI administered as two puffs BID
Study: NCT01386632
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo PO or per G-tube twice a day for 8 weeks given in combination with Cisplatin.
Study: NCT00443820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (placebo) once daily for 48 weeks
Study: NCT00443820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (placebo) once daily for 24 weeks
Study: NCT03493282
Drug: Active Treatment- CT1812 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT1812
Study: NCT03493282
Drug: Active Treatment- CT1812 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT1812
Study: NCT03493282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT01366976
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1g every 6 hours for 4 doses over 24 hours
Study: NCT01377844
Drug: EGT0001442
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01377844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02447497
Drug: 3M CHG/IPA Surgical Skin Preparation - Inguinal Region
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
Study: NCT00027924
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01889173
Drug: TNX-102-B SL Tablets at 2.8 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x TNX-102-B SL Tablet (with sodium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
Study: NCT01059643
Drug: LY2523355
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a 1-hour infusion on Days 1, 2 and 3 of a 21 day cycle; for up to 2 cycles (4 cycles for prostate cancer patients). Additional cycles administered based on patient response assessment.
Study: NCT00246337
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match assigned treatment arm; one orally-administered dose
Study: NCT00246337
Drug: MK0974
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0974 50 mg; one orally-administered dose
Study: NCT00246337
Drug: MK0974
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0974 100 mg; one orally-administered dose
Study: NCT00246337
Drug: MK0974
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0974 200 mg; one orally-administered dose
Study: NCT03185143
Drug: Naltrexone and Acetaminophen Combination
Normalized name: bupropion and naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat a single Qualified Migraine attack.
Study: NCT03185143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule contains a sham for component A and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
Study: NCT01209156
Drug: [18F] PBR111
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be injected with 5mCi (not to exceed a maximum of 5.5 mCi) of \[18F\]PBR111, followed by PET imaging.
Study: NCT00176644
Drug: Transdermal Estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: application of 4 transdermal estradiol patches, each patch releases a dose of 0.1 mg/day for a total dose of 0.4 mg/day. All four patches will be changed every 7 days. This continuous weekly schedule will be followed until the patient goes off-study.~The patch will be applied to a clean, dry, intact area of the lower abdomen or the upper quadrant of the buttock. The sites should be rotated weekly. If a patch falls off during the 7 days, a new patch will be applied for the remainder of the 7 day period. At the end of the 7 days all four patches will be changed.
Study: NCT00246337
Drug: MK0974
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0974 300 mg; one orally-administered dose
Study: NCT00246337
Drug: MK0974
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0974 400 mg; one orally-administered dose
Study: NCT00246337
Drug: MK0974
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0974 600 mg; one orally-administered dose
Study: NCT00653185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYR-472 placebo-matching tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
Study: NCT01686152
Drug: Zyclara®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00311519
Drug: Hylenex
Normalized name: Hylenex
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02004899
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After obtaining informed consent, patients are randomized into one of two treatment groups or a control group by a computer generated random number table. After confirmation of epidural placement following test dose administration, a loading dose of 10 ml 0.08% Bupivacaine containing 20 mcg Fentanyl is administered after adding 1.6 ml 0.9% NaCl (Sodium Chloride) in the control group (F20).
Study: NCT01226511
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02174913
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 1-2 mcg/kg iv for induction and then 0.5-1.0 mcg/kg/hr infusion is used for analgesic.
Study: NCT03381404
Drug: [14C] MT-8554
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-C MT-8554
Study: NCT00435435
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00435435
Drug: Naltexone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02081625
Drug: NS-065/NCNP-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: NS-065/NCNP-01 for Infusion is packaged as 25 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline as follows:~Cohort 1: 1.25mg/kg once weekly for 12 weeks; Cohort 2: 5.0mg/kg once weekly for 12 weeks; Cohort 3: 20.0mg/kg once weekly for 12 weeks
Study: NCT02612480
Drug: Acetylsalicylic acid lysinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 day treatment of acetylsalicyclic acid 1d80mg after a loading dose of 160mg
Study: NCT02612480
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 day treatment with placebo
Study: NCT03651102
Drug: Thalidomide and Hydroxyurea
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage: Thalidomide 1-4mg/kg/day, Hydroxyurea 10-20mg/kg/day
Study: NCT00638456
Drug: placebo plus Prevacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
Study: NCT05085106
Drug: Placebo eye drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye drop: 0.0%, 1 drop will be instilled as instructed over one day in single-dose study; 0.0%, 1 drop per time, four times each day and for seven days totally in multiple-dose study.
Study: NCT04874142
Drug: YYC506-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: single administration
Study: NCT04601103
Drug: No SLS toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toothpaste no Sodium Lauryl Sulfate
Study: NCT04601103
Drug: Medium SLS toothpaste
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less than or equal to X ppm Sodium Lauryl Sulfate
Study: NCT00993759
Drug: 3804-250A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.2 ml applied topically after hand washing and at least every 3 hours while awake.
Study: NCT00578344
Drug: Cyclophosphamide and MESNA
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day -5 through Day -2; Cyclophosphamide 50 mg/kg + MESNA.
Study: NCT02165202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to the placebo arm will receive oral placebo capsules prior to injection of saline solution (0.9%NaCI). Participants will be observed while taking the study product by site staff on approximately six occasions during the first two weeks of the oral run-in at Week 0 (Enrollment), at Week 2 (Oral Run-in Safety Visit), and on four separate DOT visits between Weeks 0 and 2. Cervicovaginal and rectal fluid will be collected for PK studies at a single follow-up visit.
Study: NCT01836523
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
Study: NCT03052517
Drug: QAW039 450 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of QAW039 450 mg once daily
Study: NCT03052517
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of Placebo once daily
Study: NCT01236898
Drug: NPC-09
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPC-09 tablet NPC-09 contains 50mg or 100mg N-acetylneuraminic acid (anhydride)
Study: NCT01303471
Drug: opioid (remifentanyl)
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of remifentanyl (opioid) will be started at different levels for each group of the randomized study : 0 ng/ml (group 0), 1 ng/ml (group 1), 3 ng/ml (group 3) or 4 ng/ml (group 4)
Study: NCT00689637
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules qd, 12 days
Study: NCT00973414
Drug: Ringer's Lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's Lactate 8 ml/kg was given intravenously before or after CSEA in cesarean section
Study: NCT04115007
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Definition of standard of care (prior to randomization):~* Radiotherapy to the prostate in de novo metastatic patients~* Radiotherapy to the pelvic lymph nodes in patients with positive pelvic nodes (given as full dose to the positive lymph node and prophylactic dose to the pelvic nodal basin)~* Long term ADT +/- intermittent treatment~* Additional therapy following tumor board meeting : new generation hormonal therapy (abiraterone, enzalutamide, apalutamide or other approved) or chemotherapy (docetaxel).
Study: NCT01993459
Drug: NaCl (sodium chloride) 0,9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: We will administer NaCl (sodium chloride) 0,9% 3ml intravenously once pre-operatively to patients just before they undergo surgery
Study: NCT03520595
Drug: Arnica 200 drug 3 pills,3 times daily for 3 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLP with ostectomy done in patients whose biologic width and crown height is insufficient
Study: NCT03520595
Drug: Diclofenac Sodium 50mg twice daily
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CLP with ostectomy done in patients whose biologic width and crown height is insufficient
Study: NCT01903954
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally b.i.d.
Study: NCT01758978
Drug: a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
Study: NCT01907061
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo or NAC will be given
Study: NCT01351675
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, once daily
Study: NCT00813709
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose matching placebo will be administered subcutaneously twice weekly. Placebo is supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 milliliter (mL).
Study: NCT00603798
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
Study: NCT06318052
Drug: Gynomunal gel treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hormone/free, vaginal moisturizing gel for women with vaginal dryness
Study: NCT03299686
Drug: CJM112
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg CJM112 (Study treatment) s.c. injection received per week for the first 4 weeks, followed by once every two weeks up to Week 12 (Day 85) + standard of care treatment.
Study: NCT03745222
Drug: Concurrent chemoradiotherapy (cCRT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide per standard of care. Radiotherapy will also be given concurrently with chemotherapy.
Study: NCT03098940
Drug: Chewing Gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the study healthy subjects will receive single doses of the various strengths of dronabinol
Study: NCT01361269
Drug: Fosmidomycin and clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study drugs will be co-administered under supervision by a study physician or nurse in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).
Study: NCT05002517
Drug: Methylprednisolone group
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone belongs to a group of medicines called corticosteroids (it works at the cellular level by reducing the production of substances that cause inflammation or allergy).
Study: NCT00206557
Drug: Estradiol/dyhydroprogestrone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04975022
Drug: N11005
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral insulin N11005, 300IU, p.o.
Study: NCT01945749
Drug: Intraarticular saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml isotonic saline mixed with 4 ml Lidocain (10 mg/ml) without adrenalin. Injections are done ultrasound guided
Study: NCT00365586
Drug: Ketoprofen Topical Patch , 20%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01702675
Drug: ACH15 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACH15 50mg capsule
Study: NCT01702675
Drug: ACH15 250 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACH15 250mg capsule
Study: NCT01702675
Drug: ACH15 500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACH15 500 mg capsule
Study: NCT01702675
Drug: ACH15 - 1000mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACH15 500mg capsule - two 500mg capsules in single dose
Study: NCT01702675
Drug: ACH15 - 2000mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACH15 500mg capsule (four 500mg capsules in one dose)
Study: NCT01702675
Drug: ACH15 - 500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACH15 - 500mg twice a day for 7 days
Study: NCT01702675
Drug: Placebo 250 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule manufactured to mimic ACH15 250 mg capsule
Study: NCT01702675
Drug: Placebo 500mg
Normalized name: placebo 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule manufactured to mimic ACH15 500 mg capsule
Study: NCT01702675
Drug: Placebo 1000mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (two 500 mg capsules in one dose)
Study: NCT01702675
Drug: Placebo 2000mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (four 500 mg capsules in one dose)
Study: NCT01702675
Drug: Placebo 500mg
Normalized name: placebo 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (500 mg capsules twice a day for 7 days)
Study: NCT00654992
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 IU/kg of normal saline intravenously before surgery
Study: NCT00785317
Drug: Angemin vs Activelle
Normalized name: estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP or 1 mg of oral E2 in continuous combination with 0.5 mg of NETA during six months.
Study: NCT00499863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch
Study: NCT03463707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Investigational product BP101, nasal spray
Study: NCT02409381
Drug: Motore
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg
Study: NCT02691728
Drug: LDV/SOF FDC
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00420992
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules, bid
Study: NCT01119430
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar pill as active comparator twice a day
Study: NCT04159649
Drug: Gonadotropins
Normalized name: GONADOTROPINS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropins without letrozol in fixed Gn RH antagonist IVF protocol